Immunocore to present at the Jefferies London Healthcare Conference
November 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity...
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
September 09, 2022 10:00 ET
|
Immunocore Holdings Limited
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
August 03, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
July 11, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
June 25, 2022 04:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
Immunocore Appoints Siddharth Kaul to its Board of Directors
June 09, 2022 07:45 ET
|
Immunocore Holdings Limited
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR)...